Ulf H Lerner

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4109409/publications.pdf

Version: 2024-02-01

179	8,592	43973	56606
papers	citations	48	83
		h-index	g-index

181	181	181	9130
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Phytocystatin CsinCPI-2 Reduces Osteoclastogenesis and Alveolar Bone Loss. Journal of Dental Research, 2022, 101, 216-225.	2.5	5
2	Estradiol and RSPO3 regulate vertebral trabecular bone mass independent of each other. American Journal of Physiology - Endocrinology and Metabolism, 2022, , .	1.8	1
3	Stimulation of Osteoclast Formation by Oncostatin M and the Role of WNT16 as a Negative Feedback Regulator. International Journal of Molecular Sciences, 2022, 23, 3287.	1.8	6
4	Anemia is associated with increased risk of non-vertebral osteoporotic fractures in elderly men: the MrOS Sweden cohort. Archives of Osteoporosis, 2022, 17, .	1.0	6
5	Stimulation of osteoclast formation and bone resorption by glucocorticoids: Synergistic interactions with the calcium regulating hormones parathyroid hormone and 1,25(OH)2-vitamin D3. Vitamins and Hormones, 2022, , 231-270.	0.7	2
6	High platelet count is associated with low bone mineral density: The MrOS Sweden cohort. Osteoporosis International, 2021, 32, 865-871.	1.3	10
7	Osteocyte- and late osteoblast-derived NOTUM reduces cortical bone mass in mice. American Journal of Physiology - Endocrinology and Metabolism, 2021, 320, E967-E975.	1.8	6
8	An<scp>ARHGAP25</scp>variant links aberrant<scp>Rac1</scp>function to earlyâ€onset skeletal fragility. JBMR Plus, 2021, 5, e10509.	1.3	4
9	RSPO3 is important for trabecular bone and fracture risk in mice and humans. Nature Communications, 2021, 12, 4923.	5.8	19
10	WNT16 is Robustly Increased by Oncostatin M in Mouse Calvarial Osteoblasts and Acts as a Negative Feedback Regulator of Osteoclast Formation Induced by Oncostatin M. Journal of Inflammation Research, 2021, Volume 14, 4723-4741.	1.6	6
11	Immunoglobulin G complexes without sialic acids enhance osteoclastogenesis but do not affect arthritisâ€mediated bone loss. Scandinavian Journal of Immunology, 2021, 93, e13009.	1.3	10
12	High Plasma Erythropoietin Predicts Incident Fractures in Elderly Men with Normal Renal Function: The MrOS Sweden Cohort. Journal of Bone and Mineral Research, 2020, 35, 298-305.	3.1	15
13	Role of Interleukins on Physiological and Pathological Bone Resorption and Bone Formation: Effects by Cytokines in The IL-1 and IL-2 Families. , 2020, , 45-66.		2
14	Role of Interleukins on Physiological and Pathological Bone Resorption and Bone Formation: Effects by Cytokines in The IL-6 and IL-10 Families. , 2020, , 67-87.		1
15	Role of Interleukins on Physiological and Pathological Bone Resorption and Bone Formation: Effects by Cytokines in The IL-12 and IL-17 Families, and by IL-3, IL-32 and IL-34. , 2020, , 88-102.		1
16	Osteoblastâ€derived NOTUM reduces cortical bone mass in mice and the NOTUM locus is associated with bone mineral density in humans. FASEB Journal, 2019, 33, 11163-11179.	0.2	24
17	Finding a Toll on the Route: The Fate of Osteoclast Progenitors After Toll-Like Receptor Activation. Frontiers in Immunology, 2019, 10, 1663.	2.2	52
18	Glucocorticoids employ the monomeric glucocorticoid receptor to potentiate vitamin D3 and parathyroid hormoneâ€“induced osteoclastogenesis. FASEB Journal, 2019, 33, 14394-14409.	0.2	11

#	Article	IF	Citations
19	Vitamin A decreases the anabolic bone response to mechanical loading by suppressing bone formation. FASEB Journal, 2019, 33, 5237-5247.	0.2	15
20	Mendelian Randomization Analysis Reveals a Causal Influence of Circulating Sclerostin Levels on Bone Mineral Density and Fractures. Journal of Bone and Mineral Research, 2019, 34, 1824-1836.	3.1	24
21	Activation of Shc1 Allows Oncostatin M to Induce RANKL and Osteoclast Formation More Effectively Than Leukemia Inhibitory Factor. Frontiers in Immunology, 2019, 10, 1164.	2.2	17
22	Activation of Toll-like receptor 2 induces B1 and B2 kinin receptors in human gingival fibroblasts and in mouse gingiva. Scientific Reports, 2019, 9, 2973.	1.6	9
23	The critical interplay between bone resorbing and bone forming cells. Journal of Clinical Periodontology, 2019, 46, 33-51.	2.3	54
24	NOTUM inhibition increases endocortical bone formation and bone strength. Bone Research, 2019, 7, 2.	5.4	57
25	Osteoporosis and skeletal dysplasia caused by pathogenic variants in SGMS2. JCI Insight, 2019, 4, .	2.3	47
26	Osteoclasts in Health and Disease. Pediatric Endocrinology Reviews, 2019, 17, 84-99.	1.2	6
27	Antibiotics with Interleukin-15 Inhibition Reduce Joint Inflammation and Bone Erosions but Not Cartilage Destruction in Staphylococcus aureus-Induced Arthritis. Infection and Immunity, 2018, 86, .	1.0	4
28	Inducible Wnt16 inactivation: WNT16 regulates cortical bone thickness in adult mice. Journal of Endocrinology, 2018, 237, 113-122.	1.2	32
29	Effects of retinoids on physiologic and inflammatory osteoclastogenesis in vitro. Journal of Leukocyte Biology, 2018, 104, 1133-1145.	1.5	4
30	WNT16 overexpression partly protects against glucocorticoid-induced bone loss. American Journal of Physiology - Endocrinology and Metabolism, 2018, 314, E597-E604.	1.8	19
31	Porcupine inhibitors impair trabecular and cortical bone mass and strength in mice. Journal of Endocrinology, 2018, 238, 13-23.	1.2	37
32	High Serum Serotonin Predicts Increased Risk for Hip Fracture and Nonvertebral Osteoporotic Fractures: The MrOS Sweden Study. Journal of Bone and Mineral Research, 2018, 33, 1560-1567.	3.1	10
33	Bone Cell Activity in Clinical Prostate Cancer Bone Metastasis and Its Inverse Relation to Tumor Cell Androgen Receptor Activity. International Journal of Molecular Sciences, 2018, 19, 1223.	1.8	24
34	Clinically relevant doses of vitamin A decrease cortical bone mass in mice. Journal of Endocrinology, 2018, 239, 389-402.	1.2	17
35	Inhibition of lipopolysaccharide-induced osteoclast formation and bone resorption in vitro and in vivo by cysteine proteinase inhibitors. Journal of Leukocyte Biology, 2017, 101, 1233-1243.	1.5	28
36	Loss of menin in osteoblast lineage affects osteocyteâ€“osteoclast crosstalk causing osteoporosis. Cell Death and Differentiation, 2017, 24, 672-682.	5.0	47

#	Article	IF	Citations
37	Inhibition of the insulin-like growth factor-1 receptor potentiates acute effects of castration in a rat model for prostate cancer growth in bone. Clinical and Experimental Metastasis, 2017, 34, 261-271.	1.7	10
38	SNX10 gene mutation leading to osteopetrosis with dysfunctional osteoclasts. Scientific Reports, 2017, 7, 3012.	1.6	43
39	Toll-Like Receptor 2 Stimulation of Osteoblasts Mediates Staphylococcus Aureus Induced Bone Resorption and Osteoclastogenesis through Enhanced RANKL. PLoS ONE, 2016, 11, e0156708.	1.1	53
40	Activation of dimeric glucocorticoid receptors in osteoclast progenitors potentiates RANKL induced mature osteoclast bone resorbing activity. Bone, 2016, 93, 43-54.	1.4	43
41	Osteoblast differentiation is enhanced by a nano-to-micro hybrid titanium surface created by Yb:YAG laser irradiation. Clinical Oral Investigations, 2016, 20, 503-511.	1.4	37
42	The bone-sparing effects of estrogen and WNT16 are independent of each other. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14972-14977.	3.3	50
43	Retinoid Receptors in Bone and Their Role in Bone Remodeling. Frontiers in Endocrinology, 2015, 6, 31.	1.5	75
44	TLR5, a novel mediator of innate immunityâ€induced osteoclastogenesis and bone loss. FASEB Journal, 2015, 29, 4449-4460.	0.2	39
45	A new WNT on the bone: WNT16, cortical bone thickness, porosity and fractures. BoneKEy Reports, 2015, 4, 669.	2.7	60
46	Porphyromonas gingivalis Stimulates Bone Resorption by Enhancing RANKL (Receptor Activator of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Chemistry, 2015, 290, 20147-20158.	1.6	91
47	Increased Eotaxin and MCP-1 Levels in Serum from Individuals with Periodontitis and in Human Gingival Fibroblasts Exposed to Pro-Inflammatory Cytokines. PLoS ONE, 2015, 10, e0134608.	1.1	55
48	Osteoblast-derived WNT16 represses osteoclastogenesis and prevents cortical bone fragility fractures. Nature Medicine, 2014, 20, 1279-1288.	15.2	303
49	Vitamin A Metabolism, Action, and Role in Skeletal Homeostasis. Endocrine Reviews, 2013, 34, 766-797.	8.9	137
50	Cysteine proteinase inhibitors regulate human and mouse osteoclastogenesis by interfering with RANK signaling. FASEB Journal, 2013, 27, 2687-2701.	0.2	32
51	Inhibition of the Insulin-Like Growth Factor-1 Receptor Enhances Effects of Simvastatin on Prostate Cancer Cells in Co-Culture with Bone. Cancer Microenvironment, 2013, 6, 231-240.	3.1	14
52	The role of cytokines in inflammatory bone loss. Immunological Investigations, 2013, 42, 555-622.	1.0	207
53	Estrogen receptor-Î± is required for the osteogenic response to mechanical loading in a ligand-independent manner involving its activation function 1 but not 2. Journal of Bone and Mineral Research, 2013, 28, 291-301.	3.1	87
54	<scp>IL</scp>â€4 and <scp>IL</scp>â€13 inhibit <scp>IL</scp>â€1Î² and <scp>TNF</scp>â€Î± induced kinin <scp>B₁</scp> and <scp>B₂</scp> receptors through a <scp>STAT6</scp>â€dependent mechanism. British Journal of Pharmacology, 2013, 169, 400-412.	2.7	26

#	Article	IF	Citations
55	Osteoclast progenitor cells present in significant amounts in mouse calvarial osteoblast isolations and osteoclastogenesis increased by BMP-2. Bone, 2013, 52, 83-92.	1.4	40
56	Activation of the liver X receptor-Î² potently inhibits osteoclastogenesis from lipopolysaccharide-exposed bone marrow-derived macrophages. Journal of Leukocyte Biology, 2013, 93, 71-82.	1.5	16
57	Low-dose prednisolone in early rheumatoid arthritis inhibits collagen type I degradation by matrix metalloproteinases as assessed by serum 1CTP--a possible mechanism for specific inhibition of radiological destruction. Rheumatology, 2013, 52, 733-742.	0.9	15
58	Interleukin 15 Mediates Joint Destruction in Staphylococcus Aureus Arthritis. Journal of Infectious Diseases, 2012, 206, 687-696.	1.9	14
59	High serum adiponectin predicts incident fractures in elderly men: Osteoporotic fractures in men (MrOS) Sweden. Journal of Bone and Mineral Research, 2012, 27, 1390-1396.	3.1	49
60	Osteoblasts, Osteoclasts, and Osteocytes: Unveiling Their Intimate-Associated Responses to Applied Orthodontic Forces. Seminars in Orthodontics, 2012, 18, 237-248.	0.8	28
61	The gut microbiota regulates bone mass in mice. Journal of Bone and Mineral Research, 2012, 27, 1357-1367.	3.1	585
62	Interleukin-4 and interleukin-13 inhibit the expression of leukemia inhibitory factor and interleukin-11 in fibroblasts. Molecular Immunology, 2012, 49, 601-610.	1.0	18
63	Porphyromonas gingivalis (Pg) a possible link between impaired oral health and acute myocardial infarction. International Journal of Cardiology, 2011, 148, 148-153.	0.8	37
64	Comparisons between the effects of calcitonin receptorâ€stimulating peptide and intermedin and other peptides in the calcitonin family on bone resorption and osteoclastogenesis. Journal of Cellular Biochemistry, 2011, 112, 3300-3312.	1.2	25
65	The neuropeptide VIP regulates the expression of osteoclastogenic factors in osteoblasts. Journal of Cellular Biochemistry, 2011, 112, 3732-3741.	1.2	24
66	Activation of Liver X Receptor (LXR) Inhibits Receptor Activator of Nuclear Factor ÎºB Ligand (RANKL)-induced Osteoclast Differentiation in an LXRÎ²-dependent Mechanism. Journal of Biological Chemistry, 2011, 286, 33084-33094.	1.6	40
67	Retinoids Stimulate Periosteal Bone Resorption by Enhancing the Protein RANKL, a Response Inhibited by Monomeric Glucocorticoid Receptor*. Journal of Biological Chemistry, 2011, 286, 31425-31436.	1.6	44
68	Development of a novel poly bisphosphonate conjugate for treatment of skeletal metastasis and osteoporosis. International Journal of Oncology, 2010, 37, 563-7.	1.4	18
69	Cytokine responses against periodontal infection: protective and destructive roles. Periodontology 2000, 2010, 52, 163-206.	6.3	242
70	Stimulation of IL-6 Cytokines in Fibroblasts by Toll-like Receptors 2. Journal of Dental Research, 2010, 89, 802-807.	2.5	29
71	Polymorphisms in the macrophage migration inhibitory factor gene and bone loss in postmenopausal women. Bone, 2010, 47, 424-429.	1.4	19
72	Glucocorticoids Suppress Bone Formation by Attenuating Osteoblast Differentiation via the Monomeric Glucocorticoid Receptor. Cell Metabolism, 2010, 11, 517-531.	7.2	346

#	Article	IF	Citations
73	Retinoids inhibit differentiation of hematopoetic osteoclast progenitors. FASEB Journal, 2009, 23, 3526-3538.	0.2	43
74	Establishment and validation of an in vitro co-culture model to study the interactions between bone and prostate cancer cells. Clinical and Experimental Metastasis, 2009, 26, 945-953.	1.7	18
75	Expression of the calcitonin receptor, calcitonin receptorâ€like receptor, and receptor activity modifying proteins during osteoclast differentiation. Journal of Cellular Biochemistry, 2008, 104, 920-933.	1.2	47
76	Kinin B1 and B2 receptor expression in osteoblasts and fibroblasts is enhanced by interleukin-1 and tumour necrosis factor-Î±. Effects dependent on activation of NF-ÎºB and MAP kinases. Bone, 2008, 43, 72-83.	1.4	57
77	IL-1Î² and TNF-Î± Regulate IL-6-type Cytokines in Gingival Fibroblasts. Journal of Dental Research, 2008, 87, 558-563.	2.5	74
78	Kinins and Neuro-osteogenic Factors. , 2008, , 1025-1057.		10
79	Calcitonin inhibits osteoclast formation in mouse haematopoetic cells independently of transcriptional regulation by receptor activator of NF-ÎºB and c-Fms. Journal of Endocrinology, 2007, 195, 415-427.	1.2	59
80	Osteoclast formation is strongly reduced both in vivo and in vitro in the absence of CD47/SIRPÎ±-interaction. Biochemical and Biophysical Research Communications, 2007, 352, 444-448.	1.0	70
81	Effects on osteoclast and osteoblast activities in cultured mouse calvarial bones by synovial fluids from patients with a loose joint prosthesis and from osteoarthritis patients. Arthritis Research and Therapy, 2007, 9, R18.	1.6	26
82	Bradykinin potentiates cytokine-induced prostaglandin biosynthesis in osteoblasts by enhanced expression of cyclooxygenase 2, resulting in increased RANKL expression. Arthritis and Rheumatism, 2007, 56, 910-923.	6.7	56
83	Bone Remodeling in Post-menopausal Osteoporosis. Journal of Dental Research, 2006, 85, 584-595.	2.5	259
84	Inflammation-induced Bone Remodeling in Periodontal Disease and the Influence of Post-menopausal Osteoporosis. Journal of Dental Research, 2006, 85, 596-607.	2.5	229
85	Glucocorticoid Regulation of Osteoclast Differentiation and Expression of Receptor Activator of Nuclear Factor-ÎºB (NF-ÎºB) Ligand, Osteoprotegerin, and Receptor Activator of NF-ÎºB in Mouse Calvarial Bones. Endocrinology, 2006, 147, 3613-3622.	1.4	88
86	Inhibition of Hormone and Cytokine-stimulated Osteoclastogenesis and Bone Resorption by Interleukin-4 and Interleukin-13 Is Associated with Increased Osteoprotegerin and Decreased RANKL and RANK in a STAT6-dependent Pathway. Journal of Biological Chemistry, 2006, 281, 2414-2429.	1.6	121
87	The neuropeptide VIP potentiates IL-6 production induced by proinflammatory osteotropic cytokines in calvarial osteoblasts and the osteoblastic cell line MC3T3-E1. Biochemical and Biophysical Research Communications, 2005, 335, 705-711.	1.0	26
88	Cytokine responses of human gingival fibroblasts to Actinobacillus actinomycetemcomitans cytolethal distending toxin. Cytokine, 2005, 30, 56-63.	1.4	80
89	Increased expression of interleukin-6 by vasoactive intestinal peptide is associated with regulation of CREB, AP-1 and C/EBP, but not NF-ÎºB, in mouse calvarial osteoblasts. Bone, 2005, 37, 513-529.	1.4	42
90	Bone resorbing activity and cytokine levels in gingival crevicular fluid before and after treatment of periodontal disease. Journal of Clinical Periodontology, 2004, 31, 475-482.	2.3	71

#	Article	IF	Citations
91	Interleukin-6 promoter polymorphism is associated with bone quality assessed by calcaneus ultrasound and previous fractures in a cohort of 75-year-old women. Osteoporosis International, 2004, 15, 820-6.	1.3	33
92	Osteoclastogenesis is decreased by cysteine proteinase inhibitors. Bone, 2004, 34, 412-424.	1.4	46
93	Family 2 cystatins inhibit osteoclast-mediated bone resorption in calvarial bone explants. Bone, 2004, 35, 689-696.	1.4	14
94	N<scp>ew</scp> M<scp>olecules in the</scp> T<scp>umor</scp> N<scp>ecrosis</scp> F<scp>actor</scp> L<scp>igand and</scp> R<scp>eceptor</scp> S<scp>uperfamilies with</scp> I<scp>mportance for</scp> P<scp>hysiological and</scp> P<scp>athological</scp> B<scp>one</scp> R<scp>esorption</scp>. Critical Reviews in Oral Biology and Medicine, 2004, 15, 64-81.	4.4	117
95	cDNA-arrays and real-time quantitative PCR techniques in the investigation of chronic achilles tendinosis. Journal of Orthopaedic Research, 2003, 21, 970-975.	1.2	160
96	IL-6, Leukemia Inhibitory Factor, and Oncostatin M Stimulate Bone Resorption and Regulate the Expression of Receptor Activator of NF-Î�ºB Ligand, Osteoprotegerin, and Receptor Activator of NF-Î�ºB in Mouse Calvariae. Journal of Immunology, 2002, 169, 3353-3362.	0.4	439
97	TNF-alpha gene polymorphism and plasma TNF-alpha levels are related to lumbar spine bone area in healthy female Caucasian adolescents. European Journal of Endocrinology, 2002, 146, 629-634.	1.9	33
98	Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones. Bone, 2002, 31, 242-251.	1.4	56
99	Characterization of bradykinin receptors in a human osteoblastic cell line. Regulatory Peptides, 2002, 103, 39-51.	1.9	20
100	Bone-resorbing Activity from Cholesterol-exposed Macrophages due to Enhanced Expression of Interleukin-Îl±. Journal of Dental Research, 2002, 81, 11-16.	2.5	34
101	Expression and regulatory role of receptors for vasoactive intestinal peptide in bone cells. Microscopy Research and Technique, 2002, 58, 98-103.	1.2	27
102	Kinins and Neuro-osteogenic Factors. , 2002, , 773-799.		2
103	Isolated rat stomach ECL cells generate prostaglandin E2 in response to interleukin-1Î², tumor necrosis factor-Î± and bradykinin. European Journal of Pharmacology, 2001, 416, 255-263.	1.7	15
104	Vasoactive Intestinal Peptide (VIP)/Pituitary Adenylate Cyclase-Activating Peptide Receptor Subtypes in Mouse Calvarial Osteoblasts: Presence of VIP-2 Receptors and Differentiation-Induced Expression of VIP-1 Receptors**The present study was supported by grants from the Swedish Medical Research Council (7525), the Swedish Rheumatism Association, the Royal 80 Year Fund of King Gustav V, the A-G Crafoord Foundation, the County Council of Vaî¨sterbotten, the Swedish Dental Society, the Swedish Society for Medic. Endocrinology, 2001, 142, 339-347.	1.4	71
105	Calcium sensing receptor gene polymorphism, circulating calcium concentrations and bone mineral density in healthy adolescent girls. European Journal of Endocrinology, 2001, 144, 257-261.	1.9	96
106	Characterization of bone resorbing activity in gingival crevicular fluid from patients with periodontitis. Journal of Clinical Periodontology, 2000, 27, 41-52.	2.3	59
107	The bone resorbing activity released by gingival fibroblasts isolated from patients with periodontitis is independent of interleukin-1. Journal of Periodontal Research, 2000, 35, 74-84.	1.4	8
108	Functional Characterization of Osteoblasts and Osteoclasts from Alkaline Phosphatase Knockout Mice. Journal of Bone and Mineral Research, 2000, 15, 1879-1888.	3.1	214

#	Article	IF	Citations
109	The Role of Skeletal Nerve Fibers in Bone Metabolism. , 2000, 10, 377-382.		17
110	The Inhibitory Effects of Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide on Osteoclast Formation Are Associated with Upregulation of Osteoprotegerin and Downregulation of RANKL and RANK. Biochemical and Biophysical Research Communications, 2000, 271, 158-163.	1.0	66
111	Microisolated Mouse Osteoclasts Express VIP-1 and PACAP Receptors. Biochemical and Biophysical Research Communications, 2000, 274, 400-404.	1.0	57
112	A peptidyl derivative structurally based on the inhibitory center of cystatin C inhibits bone resorption in vitro. Bone, 2000, 26, 451-459.	1.4	34
113	Vasoactive intestinal peptide regulates osteoclast activity via specific binding sites on both osteoclasts and osteoblasts. Bone, 2000, 27, 803-810.	1.4	74
114	Osteoclast formation and resorption. Matrix Biology, 2000, 19, 107-120.	1.5	88
115	Synergistic interactions of bradykinin, thrombin, interleukin 1 and tumor necrosis factor on prostanoid biosynthesis in human periodontal-ligament cells. Archives of Oral Biology, 1998, 43, 253-260.	0.8	27
116	Gingival crevicular fluid from patients with periodontitis contains bone resorbing activity. European Journal of Oral Sciences, 1998, 106, 778-787.	0.7	22
117	Gutta-percha-stimulated mouse macrophages release factors that activate the bone resorptive system of mouse calvarial bone. European Journal of Oral Sciences, 1998, 106, 872-881.	0.7	16
118	Prostaglandin-Independent Stimulation of Bone Resorption in Mouse Calvariae and in Isolated Rat Osteoclasts by Thyroid Hormones (T4, and T3). Experimental Biology and Medicine, 1998, 217, 153-161.	1.1	8
119	Bacteria Inhibit Biosynthesis of Bone Matrix Proteins in Human Osteoblasts. Clinical Orthopaedics and Related Research, 1998, 346, 244???254.	0.7	10
120	Cystatin C, an inhibitor of bone resorption produced by osteoblasts. Acta Physiologica Scandinavica, 1997, 161, 81-92.	2.3	68
121	The Role of the Kallikreinâ€"Kinin System in Inflammation-induced Bone Metabolism. , 1997, , 219-234.		5
122	Differential effects of glucocorticoids on bone resorption in neonatal mouse calvariae stimulated by peptide and steroid-like hormones. Journal of Endocrinology, 1997, 155, 513-521.	1.2	29
123	Bradykinin and thrombin synergistically potentiate interleukin 1 and tumour necrosis factor induced prostanoid biosynthesis in human dental pulp fibroblasts. Cytokine, 1996, 8, 168-177.	1.4	24
124	Stimulation of neonatal mouse calvarial bone resorption by the glucocorticoids hydrocortisone and dexamethasone. Journal of Bone and Mineral Research, 1996, 11, 1419-1429.	3.1	38
125	Transforming growth factor-Î² stimulates bone resorption in neonatal mouse calvariae by a prostaglandin-unrelated but cell proliferation-dependent pathway. Journal of Bone and Mineral Research, 1996, 11, 1628-1639.	3.1	21
126	Effects and interactions of tumour necrosis factor alpha and bradykinin on interleukin-1 production in gingival fibroblasts. Journal of Periodontal Research, 1995, 30, 186-191.	1.4	17

#	Article	IF	Citations
127	Effects of bradykinin and thrombin on prostaglandin formation, cell proliferation and collagen biosynthesis in human dental-pulp fibroblasts. Archives of Oral Biology, 1995, 40, 247-256.	0.8	32
128	Stimulation of bone resorption by the kallikrein-kinin system and the coagulation cascade. Acta Orthopaedica, 1995, 66, 45-50.	1.4	2
129	Regulation of bone metabolism by the kallikrein-kinin system, the coagulation cascade, and the acute-phase reactants. Oral Surgery, Oral Medicine, and Oral Pathology, 1994, 78, 481-493.	0.6	54
130	Cholera toxin-stimulated bone resorption in cultured mouse calvarial bones not inhibited by calcitonin: A possible interaction at the stimulatory g protein. Journal of Bone and Mineral Research, 1994, 9, 1927-1934.	3.1	1
131	Role of protein kinase C in bradykinin-induced prostaglandin formation in osteoblasts. European Journal of Pharmacology, 1993, 244, 111-117.	2.7	19
132	Epidermal growth factor potentiates interleukin 1 and tumour necrosis factor-induced prostaglandin biosynthesis in human gingival fibroblasts. Cytokine, 1993, 5, 198-204.	1.4	28
133	The phenytoin metabolite p-HPPH upregulates prostaglandin biosynthesis in human gingival fibroblasts challenged to interleukin-1. Life Sciences, 1993, 53, 503-515.	2.0	5
134	Bone-resorbing activity of different periprosthetic tissues in aseptic loosening of total hip arthroplasty. Bone and Mineral, 1993, 20, 67-78.	2.0	13
135	Tumor necrosis factors Î± and Î² can stimulate bone resorption in cultured mouse calvariae by a Prostaglandin-independent mechanism. Journal of Bone and Mineral Research, 1993, 8, 147-155.	3.1	62
136	Coffee Drinking: A Minor Risk Factor for Bone Loss and Fractures. Age and Ageing, 1992, 21, 20-26.	0.7	55
137	Phenytoin potentiates interleukinâ€1â€induced prostaglandin biosynthesis in human gingival fibroblasts. British Journal of Pharmacology, 1992, 106, 574-578.	2.7	19
138	Caffeine has the capacity to stimulate calcium release in organ culture of neonatal mouse calvaria. Calcified Tissue International, 1992, 51, 424-428.	1.5	9
139	Effects of parathyroid hormone on cyclic AMP-formation and cytoplasmic free Ca2+ in the osteosarcoma cell line UMR 106-01. Bioscience Reports, 1992, 12, 207-214.	1.1	10
140	On the signal transducing mechanisms involved in the synergistic interaction between interleukin-1 and bradykinin on prostaglandin biosynthesis in human gingival fibroblasts. Bioscience Reports, 1992, 12, 263-271.	1.1	21
141	Haptoglobin-stimulated bone resorption in neonatal mouse calvarial bones in vitro. Arthritis and Rheumatism, 1992, 35, 587-591.	6.7	13
142	Human cystatin C, a cysteine proteinase inhibitor, inhibits bone resorption in vitro stimulated by parathyroid hormone and parathyroid hormone-related peptide of malignancy. Journal of Bone and Mineral Research, 1992, 7, 433-440.	3.1	79
143	Neuroendocrine regulation of cyclic AMP formation in osteoblastic cell lines (UMR-106â€“01, ROS 17/2.8,) Tj ETQq1 1 0.784314 rgBT	3.1	129
144	Thrombin increases cytoplasmic Ca2+ and stimulates formation of prostaglandin E2 in the osteoblastic cell line MC3T3-El. Bone and Mineral, 1991, 12, 81-90.	2.0	25

#	Article	IF	Citations
145	Comparison of human interleukin-1Î² and its 163â€“171 peptide in bone resorption and the immune response. Cytokine, 1991, 3, 141-148.	1.4	32
146	Bradykinin synergistically potentiates interleukin-1 induced bone resorption and prostanoid biosynthesis in neonatal mouse calvarial bones. Biochemical and Biophysical Research Communications, 1991, 175, 775-783.	1.0	28
147	Haptoglobin synergistically potentiates bradykinin and thrombin induced prostaglandin biosynthesis in isolated osteroblasts. Biochemical and Biophysical Research Communications, 1991, 178, 343-351.	1.0	24
148	Effects of phorbol esters and pertussis toxin on calcitonin-stimulated accumulation of cyclic AMP in neonatal mouse calvarial bones. Calcified Tissue International, 1991, 49, 284-287.	1.5	4
149	Bradykinin B1 and B2 receptor agonists synergistically potentiate interleukin-1-induced prostaglandin biosynthesis in human gingival fibroblasts. Inflammation, 1991, 15, 427-436.	1.7	70
150	Bradykinin induces formation of inositol phosphates and causes an increase in cytoplasmic Ca2+ in the osteoblastic cell line MC3T3-E1. Journal of Bone and Mineral Research, 1991, 6, 443-452.	3.1	25
151	In vitro studies on bone resorption in neonatal mouse calvariae using a modified dissection technique giving four samples of bone from each calvaria. Journal of Bone and Mineral Research, 1991, 6, 543-550.	3.1	48
152	On the role of cyclic AMP as a mediator of bone resorption: Î³-Interferon completely inhibits cholera toxin- and forskolin-induced but only partially inhibits parathyroid hormone-stimulated 45Ca release from mouse calvarial bones. Journal of Bone and Mineral Research, 1991, 6, 551-560.	3.1	9
153	Bradykinin-induced burst of prostaglandin formation in osteoblasts is mediated via B2 bradykinin receptors. Journal of Bone and Mineral Research, 1991, 6, 807-815.	3.1	26
154	Bradykinin stimulates prostaglandin E2 formation in isolated human osteoblast-like cells. Bioscience Reports, 1990, 10, 121-126.	1.1	20
155	Stimulation of bone resorption and cell proliferation in vitro by human gingival fibroblasts from patients with periodontal disease. Bone and Mineral, 1990, 10, 225-242.	2.0	9
156	Evidence for BK₁ bradykininâ€receptorâ€mediated prostaglandin formation in osteoblasts and subsequent enhancement of bone resorption. British Journal of Pharmacology, 1990, 101, 382-386.	2.7	36
157	Thrombin and bradykinin enhance prostaglandin production in human peripheral blood monocytes. Journal of Oral Pathology and Medicine, 1989, 18, 246-250.	1.4	23
158	Forskolin sensitizes parathyroid hormone-induced cyclic AMP response, but not the bone resorptive effect, in mouse calvarial bones. Bone and Mineral, 1989, 5, 169-181.	2.0	9
159	Bradykinin stimulates production of prostaglandin E2 and prostacyclin in murine osteoblasts. Bone and Mineral, 1989, 5, 139-154.	2.0	52
160	Renal cell carcinoma in tissue culture secretes nondialyzable product that stimulates bone resorption in organ-cultured mouse calvaria. Journal of Bone and Mineral Research, 1989, 4, 365-378.	3.1	6
161	Parathyroid hormone stimulates prostanoid formation in mouse calvarial bones. European Journal of Endocrinology, 1989, 120, 357-361.	1.9	9
162	Stimulation of bone resorption in cultured mouse calvaria by met-lys-bradykinin. Journal of Periodontal Research, 1988, 23, 75-77.	1.4	13

#	Article	IF	Citations
163	Blood coagulation and bone metabolism: some characteristic of the bone resorptive effect of thrombin in mouse calvarial bones in vitro. Biochimica Et Biophysica Acta - General Subjects, 1988, 964, 309-318.	1.1	36
164	Calcitonin-like effects of forskolin and choleratoxin on surface area and motility of isolated rabbit osteoclasts. Journal of Bone and Mineral Research, 1988, 3, 611-619.	3.1	21
165	Effects of cholera toxin on cyclic AMP accumulation and bone resorption in cultured mouse calvaria. Biochimica Et Biophysica Acta - Molecular Cell Research, 1987, 930, 378-391.	1.9	13
166	Effects of four bisphosphonates on bone resorption, lysosomal enzyme release, protein synthesis and mitotic activities in mouse calvarial bones in vitro. Bone, 1987, 8, 179-189.	1.4	48
167	Prostaglandin E2 causes a transient inhibition of mineral mobilization, matrix degradation, and lysosomal enzyme release from mouse calvarial bonesIn Vitro. Calcified Tissue International, 1987, 40, 323-331.	1.5	44
168	Bradykinin, a new potential mediator of inflammation-induced bone resorption. Arthritis and Rheumatism, 1987, 30, 530-540.	6.7	102
169	Human gingival fibroblasts secrete non-dialyzable, prostanoid-independent products which stimulate bone resorption in vitro. Journal of Periodontal Research, 1987, 22, 284-289.	1.4	15
170	Modifications of the mouse calvarial technique improve the responsiveness to stimulators of bone resorption. Journal of Bone and Mineral Research, 1987, 2, 375-383.	3.1	102
171	Comparative study of the effects of cyclic nucleotide phosphodiesterase inhibitors on bone resorption and cyclic AMP formation invitro. Biochemical Pharmacology, 1986, 35, 4177-4189.	2.0	24
172	Transient inhibition on calcium mobilization from cultured mouse calvarial bones by the adenylate cyclase stimulator forskolin. Acta Physiologica Scandinavica, 1984, 120, 159-160.	2.3	20
173	Adenine nucleotide levels and adenosine metabolism in cultured calvarial bone. Acta Physiologica Scandinavica, 1984, 120, 551-555.	2.3	1
174	Indomethacin inhibits bone resorptionin vitro without affecting bone collagen synthesis. Agents and Actions, 1982, 12, 466-470.	0.7	15
175	Delayed stimulatory effect of cyclic AMP on bone resorption in vitro. European Journal of Endocrinology, 1981, 97, 281-288.	1.9	10
176	Indomethacin Inhibits Bone Resorption and Lysosomal Enzyme Release from Bone in Organ Culture. Scandinavian Journal of Rheumatology, 1980, 9, 149-156.	0.6	34
177	Inhibition of bone resorption and lysosomal enzyme release from calvarial bones cultured for 24 hours: synergism between cyclic AMP analogues and phosphodiesterase inhibitors. European Journal of Endocrinology, 1980, 94, 138-144.	1.9	18
178	Influence of Diphenylhydantoin on Lysosomal Enzyme Release during Bone Resorption in Vitro. Acta Pharmacologica Et Toxicologica, 1980, 47, 144-150.	0.0	23
179	Vasoactive Intestinal Peptide (VIP)/Pituitary Adenylate Cyclase-Activating Peptide Receptor Subtypes in Mouse Calvarial Osteoblasts: Presence of VIP-2 Receptors and Differentiation-Induced Expression of VIP-1 Receptors*The present study was supported by grants from the Swedish Medical Research Council (7525), the Swedish Rheumatism Association, the Royal 80 Year Fund of King Gustav V, the A-G Crafoord Foundation, the County Council of Vaˆsterbotten, the Swedish Dental Society, the Swedish Society for Medica. , 0, .		20